N van Zandwijk
Overview
Explore the profile of N van Zandwijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
1954
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Linton A, Cheng Y, Griggs K, Schedlich L, Kirschner M, Gattani S, et al.
Br J Cancer
. 2018 Feb;
118(6):e13.
PMID: 29438360
This corrects the article DOI: 10.1038/bjc.2017.85.
2.
Linton A, Pavlakis N, OConnell R, Soeberg M, Kao S, Clarke S, et al.
Br J Cancer
. 2014 Sep;
111(9):1860-9.
PMID: 25188323
Background: Although the prognosis of most patients presenting with malignant pleural mesothelioma (MPM) is poor, a small proportion survives long term. We investigated factors associated with survival in a large...
3.
Kao S, van Zandwijk N, Clarke S
Br J Cancer
. 2014 Apr;
111(12):2376.
PMID: 24714747
No abstract available.
4.
Linton A, Cheng Y, Griggs K, Schedlich L, Kirschner M, Gattani S, et al.
Br J Cancer
. 2013 Dec;
110(2):510-9.
PMID: 24327015
Background: Malignant pleural mesothelioma (MPM) is an aggressive tumour originating in the thoracic mesothelium. Prognosis remains poor with 9- to 12-month median survival, and new targets for treatments are desperately...
5.
Reid G, Pel M, Kirschner M, Cheng Y, Mugridge N, Weiss J, et al.
Ann Oncol
. 2013 Oct;
24(12):3128-35.
PMID: 24148817
Background: Malignant pleural mesothelioma (MPM) is recalcitrant to treatment and new approaches to therapy are needed. Reduced expression of miR-15/16 in a range of cancer types has suggested a tumour...
6.
Kao S, Clarke S, Vardy J, Corte P, Clarke C, van Zandwijk N
Intern Med J
. 2012 Aug;
43(4):402-10.
PMID: 22909129
Background: The silent epidemic of mesothelioma in Australia is steadily increasing, and 30% of cases occur in New South Wales (NSW). Aim: To describe the patterns of care and outcomes...
7.
Kappers I, Vollebergh M, van Tinteren H, Korse C, Nieuwenhuis L, Bonfrer J, et al.
Ecancermedicalscience
. 2012 Jan;
4:178.
PMID: 22276032
Background: In patients with non-small cell lung cancer (NSCLC), a higher response rate can be achieved with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) when selection for therapy is guided...
8.
Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au J, Blasinska-Morawiec M, et al.
Ann Oncol
. 2011 Apr;
23(1):72-77.
PMID: 21464154
Background: This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy in patients with non-small-cell lung cancer (NSCLC). Patients And Methods: Chemotherapy-naive patients...
9.
Murrer L, Marijnissen J, Baas P, van Zandwijk N, Star W
Lasers Med Sci
. 2010 Aug;
12(3):253-9.
PMID: 20803333
This paper presents a design of an applicator for light delivery and light dosimetry during endobronchial photodynamic therapy (EB-PDT). The design incorporates a linear diffuser that is fixed in the...
10.
Kao S, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N
Intern Med J
. 2010 Mar;
40(11):742-50.
PMID: 20298508
Malignant mesothelioma (MM) is an aggressive tumour that commonly affects the mesothelial surfaces of the pleural and peritoneal cavities, and occasionally, the tunica vaginalis and the pericardium. Formerly a rare...